A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

NCT07578337 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Untreated
Advanced Pancreatic Cancer

Interventions

DRUG: Gemcitabine (1000 mg/m2)
DRUG: Nab-paclitaxel (Abraxane)
DRUG: NLM-001
DRUG: Botensilimab
DRUG: Balstililmab

Sponsor

Nelum Corp

Collaborators

[object Object]
[object Object]